PUBLISHER: TechNavio | PRODUCT CODE: 2126055
PUBLISHER: TechNavio | PRODUCT CODE: 2126055
Global Atherosclerosis Therapeutics Market 2026-2030
The global atherosclerosis therapeutics market is forecasted to grow by USD 3006.9 mn during 2025-2030, accelerating at a CAGR of 4.7% during the forecast period. The report on the global atherosclerosis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cardiovascular disease prevalence rates, technological advancements in drug development, growing focus on combination therapies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.5% |
| CAGR | 4.7% |
| Incremental Value | $3006.9 mn |
Technavio's global atherosclerosis therapeutics market is segmented as below:
By Product
- Small molecules
- Biologics
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By End-User
- Geriatric population
- High risk groups
- Middle aged adults
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the technological breakthroughs in biologics and delivery as one of the prime reasons driving the global atherosclerosis therapeutics market growth during the next few years. Also, expansion of precision medicine and diagnostics and expansion of lipoprotein lowering innovations will lead to sizable demand in the market.
The report on the global atherosclerosis therapeutics market covers the following areas:
- Global atherosclerosis therapeutics market sizing
- Global atherosclerosis therapeutics market forecast
- Global atherosclerosis therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global atherosclerosis therapeutics market vendors that include Alnylam Pharmaceuticals Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., CRISPR Therapeutics AG, CSL Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Esperion Therapeutics Inc., LIB Therapeutics Inc., Merck and Co. Inc., NewAmsterdam Pharma Co N.V., Novartis AG, Novo Nordisk AS, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Shanghai Junshi Biosciences Co. Ltd.. Also, the global atherosclerosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Atherosclerosis Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Atherosclerosis Therapeutics Market 2020 - 2024 ($ million)
- 5.2 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ million)
- 5.3 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
- 5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Atherosclerosis Therapeutics Market
- 6.2 Impact of geopolitical conflicts on Global Atherosclerosis Therapeutics Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Product
- 8.1 Market segments
- 8.2 Comparison by Product
- 8.3 Small molecules - Market size and forecast 2025-2030
- 8.4 Biologics - Market size and forecast 2025-2030
- 8.5 Market opportunity by Product
- Market opportunity by Product ($ million)
9 Market Segmentation by Distribution Channel
- 9.1 Market segments
- 9.2 Comparison by Distribution Channel
- 9.3 Hospital pharmacies - Market size and forecast 2025-2030
- 9.4 Retail pharmacies - Market size and forecast 2025-2030
- 9.5 Online pharmacies - Market size and forecast 2025-2030
- 9.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
10 Market Segmentation by End-user
- 10.1 Market segments
- 10.2 Comparison by End-user
- 10.3 Geriatric population - Market size and forecast 2025-2030
- 10.4 High risk groups - Market size and forecast 2025-2030
- 10.5 Middle aged adults - Market size and forecast 2025-2030
- 10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Thailand - Market size and forecast 2025-2030
- 12.5.6 Indonesia - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Argentina - Market size and forecast 2025-2030
- 12.6.5 South Africa - Market size and forecast 2025-2030
- 12.6.6 Israel - Market size and forecast 2025-2030
- 12.6.7 Turkey - Market size and forecast 2025-2030
- 12.6.8 Colombia - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising cardiovascular disease prevalence rates
- Technological advancements in drug development
- Growing focus on combination therapies
- 13.2 Market challenges
- High cost of innovative therapies
- Complex regulatory and approval hurdles
- Severe adverse effects and toxicity
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Technological breakthroughs in biologics and delivery
- Expansion of precision medicine and diagnostics
- Expansion of lipoprotein lowering innovations
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.5 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.6 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.7 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.8 CSL Ltd.
- CSL Ltd. - Overview
- CSL Ltd. - Business segments
- CSL Ltd. - Key offerings
- CSL Ltd. - Segment focus
- SWOT
- 15.9 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key news
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
- 15.10 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- 15.11 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.12 NewAmsterdam Pharma Co N.V.
- NewAmsterdam Pharma Co N.V. - Overview
- NewAmsterdam Pharma Co N.V. - Product / Service
- NewAmsterdam Pharma Co N.V. - Key offerings
- SWOT
- 15.13 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.14 Novo Nordisk AS
- Novo Nordisk AS - Overview
- Novo Nordisk AS - Business segments
- Novo Nordisk AS - Key offerings
- Novo Nordisk AS - Segment focus
- SWOT
- 15.15 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.16 Regeneron Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc. - Overview
- Regeneron Pharmaceuticals Inc. - Product / Service
- Regeneron Pharmaceuticals Inc. - Key news
- Regeneron Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.17 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.18 Shanghai Junshi Biosciences Co. Ltd.
- Shanghai Junshi Biosciences Co. Ltd. - Overview
- Shanghai Junshi Biosciences Co. Ltd. - Product / Service
- Shanghai Junshi Biosciences Co. Ltd. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
